Jordyn Sava is an assistant editor for Targeted Oncology.
Ultra-Low Dose of Radiation Shows Promise in Orbital Indolent B-Cell Lymphomas
November 28th 2022In an interview with Targeted Oncology, Chelsea C. Pinnix discussed the results of a phase 2 study and how these promising results will shift the treatment paradigm of patients with orbital indolent B-cell lymphoma.
Pralsetinib Shows Positive Phase 1/2 Results in RET Fusion+ NSCLC
November 26th 2022Updated analysis from the phase 1/2 ARROW study evaluating pralsetinib in patients with RET fusion-positive non–small cell lung cancer showed the agent to be well tolerated and to elicit clinical activity at a dose of 400 mg daily.
Afami-cel Elicits Durable Responses With Tolerable Safety in Pre-Treated Synovial Sarcoma
November 22nd 2022With an overall response rate of 38.6% and a consistent safety profile of that seen in prior trials, afamitresgene autoleucel continues to show clinical responses in patients with late-stage synovial sarcoma.
CD19-/CD22-CAR T Cells Elicits Durable Remissions in Children With R/R B-Cell ALL
November 22nd 2022In pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia, complete remissions were achieved in 99.0% of patients and their overall 12-month event-free survival was 73.5% with CD19-/CD22-chimeric antigen receptor therapy.
Managing Patients in the Changing Treatment Landscape of ALL
November 21st 2022In an interview with Targeted Oncology, Mark R. Litzow, MD, discussed managing patients with different subtypes of ALL and the session he was a part of during the National Comprehensive Cancer Network 2022 Annual Congress: Hematologic Malignancies.
Study Looks for Ways to Reduce Incidence of Tobacco-Associated Pancreatic Cancer
November 17th 2022In an interview with Targeted Oncology, Nagaraj Nagathihalli, PhD, further explained the basis behind his study examining tobacco-associated pancreatic cancer and his plans to improve overall survival in this patient population.
PSMA-PET SUVmean Linked With Favorable Response to 177Lu-PSMA-617 in mCRPC
November 17th 2022Findings from the phase 2 TheraP trial showed 177Lu-PSMA-617 to result in a higher prostate-specific antigen response rate vs with cabazitaxel in patients with metastatic castration-resistant prostate cancer.
Phase 3 FRUTIGA Study of Fruquintinib Elicits Positive Results in Gastric/GEJ Cancers
November 16th 2022Fruquintinib plus paclitaxel demonstrated improvements in progression-free survival, objective response rate, disease control rate, and more, in patients with advanced gastric or gastroesophageal junction adenocarcinoma.
Best Uses of Transplantation for Patients With Peripheral T-Cell Lymphoma
November 15th 2022Randomized studies examining patients with peripheral T-cell lymphoma regarding the role of transplant are lacking and more research is needed to personalize therapy for patients based on subtype, biomarkers, mutational profiling, and radiographic parameters.
FDA Approves Mirvetuximab Soravtansine in FRα-High Platinum-Resistant Ovarian Cancer
November 14th 2022Mirvetuximab soravtansine has been granted FDA accelerated approval for use in patients with folate receptor alpha-high platinum-resistant ovarian cancer who have received prior treatment with 1 to 3 prior systemic therapies.
FDA Approves Brentuximab Vedotin for Pediatric Patients With High-Risk Hodgkin Lymphoma
November 10th 2022Based on results from the phase 3 AHOD1331 trial, the FDA has approved brentuximab vedotin in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide in pediatric patients with high-risk classical Hodgkin lymphoma.
Novel IO Vaccine Induces Immune Response HPV16-Positive Tumors
November 9th 2022A first-in-human study investigating the safety and immunogenicity of amplivant adjuvant and human papillomavirus type 16 synthetic long peptides demonstrated highly favorable safety and tolerability when used as an intradermal therapeutic vaccine.